Search
Hymecromone
go.drugbank.com/drugs/DB07118InvestigationalCategories: Compounds used in a research, industrial, or household settingNitecapone
go.drugbank.com/drugs/DB20402ExperimentalNitecapone is a small molecule drug. Nitecapone has a monoisotopic molecular weight of 265.06 Da.
Categories: Compounds used in a research, industrial, or household settingD-Serine
go.drugbank.com/drugs/DB03929ApprovedInvestigationalWithdrawnA non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
Cetilistat
go.drugbank.com/drugs/DB06586InvestigationalCetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236
Quinaprilat
go.drugbank.com/drugs/DB14217ExperimentalThe active metabolite of the prodrug quinapril.
Categories: Agents Acting on the Renin-Angiotensin SystemPhenylbutazone
go.drugbank.com/drugs/DB00812ApprovedVet approvedWithdrawnIt is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). … Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Synonyms: 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine, 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedioneAD 337
go.drugbank.com/drugs/DB05725InvestigationalAD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). … The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).